

Tables

1.1	Costs and effects for alternative gallstone treatments	16
1.2	Cost and effect per patient for worksite care and regular care	18
1.3	Comparison of CBA and CEA study reports from 1979 to 1990	21
1.4	Detection rates for successive stool guaiac tests	24
1.5	Evaluation of neo-natal intensive care treatment	26
2.1	Short run production function for lengths of stay (LOS)	36
2.2	Short run cost curves for lengths of stay (LOS)	36
2.3	Long run production function for lengths of stay (LOS)	38
2.4	Discount factors for alternative time horizons and interest rates	40
2.5	Cumulative expected savings per quitter at time of cessation (\$)	41
2.6	Reference requirements for 5 treatments (per 100 bed days)	47
2.7	Costs per patient for ulcer treatment	49
2.8	Inflation-controlled hospital costs for total knee arthroplasty (\$)	52
2.9	Lifetime costs of HIV (in Australian \$)	54
2.10	Costs of different treatments before and after treatment (\$)	57
3.1	Percent of cases where RCC-estimated costs are within 10% of RVU-estimated costs	71
3.2	Marginal cost of acute inpatient care (\$)	73
3.3	Per visit costs for hospital outpatient care by type of output (\$)	74
3.4	DRGs that give different profitability outcomes using RVUs and RCCs	75
3.5	Resource based relative values and Medicare charges	78
3.6	Estimates of the share of the physician's bill that counts as costs	81
3.7	Hypothetical translation of a patient's bill: charges to costs	82
3.8	Hypothetical use of cost centers (\$)	83
4.1	Consequences of increased taxes in consumer surplus loss to drinkers and lives saved	99
4.2	Literature estimates of costs and benefits on a comparable basis	102

4.3	Comparison of optimal and actual policies	104
4.4	Internal rates of return on polio research under a variety of assumptions	107
4.5	Sensitivity analysis for JE vaccination program in Thailand	108
5.1	Estimates of the marginal cost of funds for the US federal government (MCF_F)	121
5.2	Estimates of the marginal cost of funds for US state governments (MCF_S)	123
5.3	Net benefits of a permanent \$1 increase in social security (1985–2060)	126
5.4	The data on prices, quantities and costs for non-federal general hospitals (1990)	128
5.5	Net benefits of privatization of non-federal general hospitals in the US	129
5.6	Weighted costs of systems of psychiatric care in Massachusetts	131
5.7	Evaluation of case management programs	134
5.8	The relation between the excess burden and the level of the tax rate	135
6.1	Hypothetical example of the cost-effectiveness paradigm	144
6.2	Hypothetical example of the cost-effectiveness paradigm with competing choices	145
6.3	Cost and effect per patient for worksite care and regular care	147
6.4	Total costs and results of the alternative strategies to diagnose deep-vein thrombosis	155
6.5	Optimal spending and CE ratio: men, income = \$18 000	157
6.6	Federal evaluation of state psychiatric hospital care	159
6.7	Determinants of decisions concerning alcohol treatment effectiveness	161
6.8	Effects and costs of screening for cervical cancer using the Pap smear	163
7.1	Programs with varying timing of costs and benefits	170
7.2	Programs with a delayed timing of costs and effects	171
7.3	Programs with costs that vary by individuals	174
7.4	Wage equation estimates	179
7.5	Estimates of social discount rates for the period 1965–89 (%)	181
7.6	Estimates and 95% lower and upper confidence limits for \bar{E}/\bar{C} in the SRTI trial	185
7.7	Confidence intervals (CI) for incremental cost-effectiveness ratios, ICD vs EP	187

8.1	Comparative cost–utility results for selected programs	195
8.2	Calculations of QWB with and without treatment	199
8.3	Top 10 priorities of the Oregon HSC initially and subsequently	200
8.4	Measures of economic evaluation of neo-natal intensive care by birth weight	205
8.5	Some extracts of cost for QALYs for competing treatments	208
8.6	Balance sheet of expected effect of demonstration program on number of people covered, services covered and financial costs	211
8.7	Cost-effectiveness ratio estimates of THA and other procedures	214
9.1	Utility values using TTO for patients versus general public by duration	220
9.2	Mean time trade-off and visual analogue scores	222
9.3	Intra-class correlation using time trade-off	224
9.4	The Rosser and Kind index of health status	227
9.5	Selected results from comparative valuation studies	233
9.6	Mean SG, TTO and RS quality weights for health state E	235
9.7	The seven health profiles included in the experiment	236
9.8	Implied rankings of the seven health profiles for different quality weights	236
9.9	Mean Spearman rank correlation coefficients between the direct rankings and the predicted rankings of RS, TTO and SG	237
9.10	Results for visual function and utility values according to visual acuity	239
9.11	Patients willing to trade time for improved vision (TTO method) and risk immediate death for improved vision (SG method)	240
9.12	Ratings of standardized health states	241
10.1	Revised disability classes for the Global Burden Disease Study based on the results of the PTO protocol used at the Geneva meeting on disability weight	251
10.2	DALY losses by age at death in Uganda	252
10.3	Comparison of DALYs versus deaths in demographically developing countries by categories of disease	252
10.4	Comparison of DALYs versus deaths by income grouping	253
10.5	Life expectancies at birth and after intervention (remaining years)	254
10.6	Utilities for health states with knee condition	259

10.7	The number of lives, life years and QALYs saved among 50-year-olds and 70-year-olds equivalent to saving one life, life year and QALY among 30-year-olds	261
10.8	Incremental cost-effectiveness analysis for sleeping sickness in Uganda	263
10.9	Apparent impact of HIV on mortality: DALYs as compared with HeaLYs, 1990	265
11.1	The value of a quality adjusted life year (1997 dollars) by study type	282
11.2	Costs of syphilis prevention (in millions of dollars, except for cost per case)	284
11.3	Costs and benefits of alternative mental health programs	287
11.4	Costs and benefits of the 55 mph speed limit decision using different numeraires	291
12.1	Estimated value of waiting list time (£ per month)	305
12.2	Monetary valuations of NHS nursing home care and hospital care for respondents with a preference for NHS nursing home care (n = 83)	317
12.3	Conjoint analysis results for the choice of medication versus surgery for the management of miscarriage	319
13.1	Price elasticities for health in Peru by income quintile	329
13.2	Weighted net benefits of case management programs with alternative sets of distribution weights (\$)	338
13.3	Number responding and stated willingness to pay as percent of family income	339
13.4	Equivalence numbers in questionnaires without and with explicit arguments	341
13.5	Numbers weights for severity of illness corresponding to PTO estimates	342
13.6	Aggregate results: percentage change in total demand accounted for by each income quintile and consumers' welfare loss as a percentage of income by income quintile	344
13.7	Disaggregated results for quantity reductions (D_i/D) by quintile	344
13.8	Disaggregated results for benefit losses as a percentage of income (B_i/Y_i) by quintile	345
13.9	Disaggregated costs and benefits of raising user fees in Peru by quintile	347